Email Updates

You are here

Home»Media

AVAC in the News

  • Why are HIV Groups Charging Gilead with Bad Behavior in New PrEP Trial?

    Gilead is not following the accepted standard for community engagement in its new pre-exposure prophylaxis (PrEP) trial, and we are among a coalition of HIV activists and organizations from Europe and North America calling them out on their bad corporate behavior. We root our criticism in the Good Participatory Practice (GPP) guidelines that were inspired, in part, by controversies in earlier PrEP trials.

    November 16, 2016
    The Body

  • Trump Likely to be Indifferent to Africa

    US president-elect Donald Trump is likely to be as indifferent to Africa as he was when he made his first foreign policy campaign speech in April—when he barely mentioned the continent.

    November 10, 2016
    Times LIve

  • HIV Antibody Safe With Hint of Efficacy

    Infusions of an antibody against HIV were safe and appeared to suppress the virus briefly when anti-retroviral medications were stopped, researchers said. But in two small phase I clinical trials, HIV rebounded within weeks of stopping standard triple-drug therapy.

    November 9, 2016
    Antibody Related Research
    MedPage Today

  • Funding Challenges Threaten HIV/AIDS Vaccines R&D

    A new report has revealed how research and development for AIDS vaccines, microbicides, pre-exposure prophylaxis using antiretroviral drugs (PrEP) and treatment as prevention (TasP) are in danger of being slowed or even sidelined because of inadequate funding.

    October 26, 2016
    HIV Vaccine
    The Herald

  • Mass Circumcision Cut HIV Acquisition

    An aggressive program of voluntary male circumcision in Kenya—a procedure shown to reduce the risk of acquiring HIV—has already prevented thousands of infections, a researcher said here.

    October 20, 2016
    Voluntary Medical Male Circumcision
    MedPage Today

  • Experts Reiterate PrEP's Effectiveness After Second Man Contracts HIV While Taking Medication

    The need for PrEP to be used in conjunction with condoms was highlighted when scientists announced that a second man taking the daily HIV-prevention pill had contracted a rare, drug-resistant strain of the virus.

    October 20, 2016
    Attitude

  • Second Case Emerges Of Someone On Daily PrEP Getting HIV

    This is the second case of a man on Truvada, the once-a-day pill that’s highly effective at preventing HIV, contracting a rare drug-resistant strain of the virus.

    October 19, 2016
    Buzz Feed

  • HIVR4P Ushers in 'Next-Gen' Prevention

    The next generation of biomedical HIV prevention will be a hot topic here at HIV Research for Prevention (HIVR4P) 2016. Long-acting novel antiretrovirals delivered through shots or implants, vaginal rings loaded with antiretrovirals and hormonal contraception, infusions of antibodies against HIV and new HIV vaccines are all on the table—and in the works.

    October 12, 2016
    MedScape

  • With global trials expanding, more HIV vaccines are put to the test

    "Vaccine developers will insert pieces of HIV in the vaccine candidate. You can't become infected from the vaccine. They insert snippets that will help the body react to the virus," explained Mitchell Warren, the executive director of AVAC, a New York City-based NGO that advocates for the accelerated ethical development of HIV vaccine and prevention options.

    October 3, 2016
    The Body

  • All Stakeholders Must Be Engaged in HIV Cure Research, Webinar Says

    Clinical trials for an HIV cure need a comprehensive, transparent engagement plan that includes educating all possible stakeholders, said Jessica Salzwedel of AVAC during a recent Stakeholder Engagement webinar based on the CUREiculum, a set of tools developed by a number of HIV organizations that provide information on HIV cure research.

    September 21, 2016
    Cure
    TheBody.com

Pages